



# BMJ Open Seroprevalence of anti-SARS-CoV-2 antibodies and risk of viral exposure among healthcare workers in the South Kivu province, eastern Democratic Republic of the Congo: a cross-sectional study

Tshass B Chasinga,<sup>1,2</sup> Jean-Paul Buhendwa Cikwanine,<sup>1,2</sup> Sarah Kribi,<sup>3</sup> Jonathan Tunangoya Yoyu ,<sup>1,4</sup> Natalie Hofmann,<sup>3</sup> Marica Grossegese,<sup>3</sup> Andreas Nitsche,<sup>3</sup> Sara Tomczyk,<sup>3</sup> Ann C Vietor,<sup>3</sup> Fabian H Leendertz,<sup>3,5</sup> Tim Eckmanns,<sup>3</sup> Aline B Kusinza,<sup>1,2</sup> Eric Munguakonkwa,<sup>2</sup> Andreas Kalk,<sup>6</sup> Maroyi Raha,<sup>1,2</sup> Nelson S Kambale,<sup>1,4</sup> Rodrigue B Ayagirwe,<sup>1</sup> Grit Schubert ,<sup>7</sup> Denis Mukwege<sup>1,2</sup>

**To cite:** Chasinga TB, Cikwanine J-PB, Kribi S, *et al*. Seroprevalence of anti-SARS-CoV-2 antibodies and risk of viral exposure among healthcare workers in the South Kivu province, eastern Democratic Republic of the Congo: a cross-sectional study. *BMJ Open* 2024;**14**:e072212. doi:10.1136/bmjopen-2023-072212

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-072212>).

GS and DM contributed equally.

Received 12 February 2023  
Accepted 20 November 2023



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Grit Schubert;  
schubertg@rki.de

## ABSTRACT

**Objectives** Healthcare workers (HCWs) are on the frontline of combating COVID-19, hence are at elevated risk of contracting an infection with SARS-CoV-2. The present study aims to measure the impact of SARS-CoV-2 on HCWs in central sub-Saharan Africa.

**Setting** A cross-sectional serological study was conducted at six urban and five rural hospitals during the first pandemic wave in the South Kivu province, Democratic Republic of the Congo (DRC).

**Participants** Serum specimens from 1029 HCWs employed during the first pandemic wave were collected between August and October 2020, and data on demographics and work-related factors were recorded during structured interviews.

**Primary and secondary outcome measures** The presence of IgG antibodies against SARS-CoV-2 was examined by ELISA. Positive specimens were further tested using a micro-neutralisation assay. Factors driving SARS-CoV-2 seropositivity were assessed by multivariable analysis.

**Results** Overall SARS-CoV-2 seroprevalence was high among HCWs (33.1%), and significantly higher in urban (41.5%) compared with rural (19.8%) hospitals. Having had presented with COVID-19-like symptoms before was a strong predictor of seropositivity (31.5%). Personal protective equipment (PPE, 88.1% and 11.9%) and alcohol-based hand sanitizer (71.1% and 28.9%) were more often available, and hand hygiene was more often reported after patient contact (63.0% and 37.0%) in urban compared with rural hospitals, respectively. This may suggest that higher exposure during non-work times in high incidence urban areas counteracts higher work protection levels of HCWs.

**Conclusions** High SARS-CoV-2 seropositivity indicates widespread transmission of the virus in this region of DRC.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This study highlights the importance of serological studies in revealing infection dynamics especially in regions with low diagnostic capacities.
- ⇒ A comprehensive set of demographic and epidemiological data of the study population permits in-depth analysis of factors affecting the exposure of healthcare workers to SARS-CoV-2.
- ⇒ The puzzling finding of higher seroprevalence despite the more frequent use of protective measures at urban, compared with rural hospitals, could not be fully resolved and warrants more investigations of the influence of exposure behaviour during non-work activities.

Given the absence of publicly reported cases during the same time period at the rural sites, serological studies are very relevant in revealing infection dynamics especially in regions with low diagnostic capacities. This, and discrepancies in the application of PPE between urban and rural sites, should be considered in future pandemic response programmes.

## INTRODUCTION

The ongoing pandemic of COVID-19, caused by SARS-CoV-2, was first detected in Africa on 25 February 2020, and approximately 1 month later, on 10 March 2020, the first case was reported in the Democratic Republic of the Congo (DRC).<sup>1</sup>

The DRC had recorded 95 173 confirmed cases and 1462 deaths as of 9 January 2023 in all 26 provinces, including South Kivu

(<https://data.who.int/dashboards/covid19/cases?n=c>). South Kivu is among the top six high-risk provinces in DRC for SARS-CoV-2 infections, with 3855 cases reported as of 29 May 2022.<sup>2</sup> During the first and second pandemic waves, antigenic rapid testing was available only in urban referral centres and general hospitals of this region, and only sporadically in a few rural hospitals. At the design and implementation of this study, only two laboratories, the Institut National de la Recherche Biomédicale of South Kivu and the Panzi Hospital, were further equipped for PCR testing and covered the 34 health zones of the South Kivu province for diagnosis and epidemiological surveillance.<sup>3</sup> PCR testing is done to detect active SARS-CoV-2 infection among suspected cases.

Narrative and systematic studies have estimated the proportion of SARS-CoV-2 infections that remain completely free of symptoms to be 17–97.5%, leading to a severe underestimation of the virus' local circulation if asymptomatic carriers are not being tested.<sup>4–6</sup> SARS-CoV-2 infection induces antibody production with potentially virus neutralising capacities, which enables tracing viral exposure by serological methods.<sup>7</sup> In light of potentially high rates of asymptomatic infection, understanding the extent to which local populations have already been exposed to the virus may, thus, contribute to effective control strategies for the spread of SARS-CoV-2. As in other parts of the world, COVID-19 has rapidly spread in healthcare workers (HCWs) such as doctors, nurses, hospital cleaners and laboratory technicians in DRC.<sup>8</sup> By being on the frontline of combating COVID-19, they remain at a higher risk of contracting the infection than other members of the community. Recent studies have reported a high seroprevalence of SARS-CoV-2 cases among asymptomatic HCWs in two different hospitals in Bukavu city, South Kivu province, suggesting a high exposure and circulation of SARS-CoV-2.<sup>3,8</sup> However, these studies were restricted to only the urban population as with many studies on SARS-CoV-2 exposure. The impact of the virus on HCWs in rural areas remains largely unknown but would be particularly relevant to investigate, as studies from other world regions indicate that low personal protective equipment (PPE) capacities and weak health infrastructure in rural health facilities may increase the local infection risk for HCWs.<sup>9</sup>

At the time that this study was initiated, despite unrestricted movement of the population between rural and urban areas of South Kivu, no cases of COVID-19 had been reported in rural areas of the province, hinting at severe under-reporting and undertesting at these areas. Thus, the main objective of this study was to measure the seroprevalence of anti-SARS-CoV-2 antibodies among HCWs in different urban and rural hospitals in the South Kivu province, eastern DRC. We also assessed potential preventative and risk factors of SARS-CoV-2 exposure. The data generated here may be useful to inform future public health actions like vaccine deployment and protection measures for the hospital workforce.

## METHODS

The results are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.

### Study design and participants

A cross-sectional study was carried out from August to October 2020 in 11 hospitals in the South Kivu province, eastern DRC: six urban hospitals (Panzi Hospital, Ciriri Hospital, Kadutu Hospital, BIOPHARM Health Centre, Nyantende Hospital and Kasenga Hospital) and five rural hospitals (Walungu Hospital, Katana Hospital, Kakwende Health Centre, Kaziba Health Centre and Kavumu Health Centre). Urban areas or cities were defined as any locality of at least 100 000 inhabitants with public facilities and economic and social infrastructures, to which a decree of the prime minister of DRC has conferred the status of a city.<sup>10</sup> Rural areas were defined by a population density of less than 400 people per square kilometre, lack of major hubs of urban life or migration (ie, no regular market, no airport or port), and absence of the status of a city conferred by the prime minister of DRC.<sup>10</sup> The hospitals in these areas were conveniently selected based on their accessibility and their status of being a reference health facility in the area. In the selected hospitals, all HCWs were invited to voluntarily participate in the survey. A total of 1029 consenting HCWs were included in this study regardless of current disease symptoms (68.6% of originally 1500 HCWs who were invited).

### Data and blood sample collection

Trained study staff first explained the study objectives and obtained written informed consent from participating HCWs. They were then asked to complete a risk factor questionnaire. Subsequently, 5 mL of venous blood was collected in an EDTA-coated tube. The sample tube was labelled according to the identifier on the corresponding participant questionnaire. On collection, participant blood samples were incubated at room temperature for approximately 30 min to allow clotting. All samples were brought directly to the Université Evangélique en Afrique/Panzi Hospital laboratory. Samples were then centrifuged for 10 min at 1500 rotations per minute and serum was collected into 2 mL cryotubes. The serum was stored at –20°C prior to serological analysis.

### Serological analysis of antibodies against SARS-CoV-2

We employed the following testing algorithm in order to reduce the false positive rate related to the cross-reaction of anti-SARS-CoV-2 antibodies with other common coronaviruses, as described by others<sup>11</sup>: All serum samples were analysed to detect the presence of SARS-CoV-2 antibodies using the semiquantitative Euroimmun SARS-CoV-2 IgG antibody ELISA kit (Euroimmun AG, Lübeck, Germany) that targets viral Spike Protein 1 (S1), following manufacturer's instructions. This assay has demonstrated a high sensitivity and specificity (94.6% and 98.0%, respectively) and has been widely used throughout European

and non-European serological studies.<sup>12</sup> Samples with testing ratios <0.5 were considered negative and were not included in further analyses, while samples with ratios ≥0.5 were repeated in duplicate with the same assay for confirmation. Among these samples, positive and borderline samples were further confirmed by a second assay, the Wantai SARS-CoV-2 Ab ELISA, for the detection of complete antibodies against SARS-CoV-2 (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China). For this assay, we used the following cut-off-values to evaluate samples: <0.9 considered negative; ≥0.9–1.1 considered borderline, and ≥1.1 confirmed as positive.

For all samples testing negative using the first Euro-immun assay, this result was considered final. For samples that had undergone repeated testing by a second Euro-immun test and turned out negative, this result was considered final. For all remaining samples, results from the Wantai assay were considered final and used in statistical data analyses.

Positive samples of which sufficient material remained were aliquoted and shipped frozen to the Robert Koch Institute in Berlin, Germany, for micro-neutralisation testing (NT). The presence of neutralising antibodies was analysed by mixing sera with heparin (1.5% final concentration), then diluting 50 µL of serum 1:10 in cell culture medium (Dulbecco's Modified Eagle Medium; 10% fetal calf serum; 2 mM L-glutamine), and subsequently mixing 1:1 with SARS-CoV-2 (strain BetaCoV/Germany/BavPat1/2020, provided by Dr Roman Woelfel, Institute for Microbiology of the German armed forces; final virus concentration in serum–virus mixture: 1000 Tissue Culture Infectious Dose<sub>50</sub>/mL). Incubation took place at room temperature for 1 hour. One hundred microlitres of diluted serum-virus mix were then added to wells of a 96-well plate containing 2×10<sup>4</sup> Vero E6 cells per well (#85020206, European Collection of Authenticated Cell Cultures, Porton Down, UK) and incubated for 5 days at 37°C, 5% CO<sub>2</sub>. After this time, each well was examined by light microscopy for a visible cytopathic effect (CPE), and the number of wells without CPE (neutralised wells) was counted. The sample dilution was tested in eight replicates. A positive control with known titre was included in parallel and back-titration of the virus stock was performed. Samples with at least one neutralised well were evaluated as positive for neutralising antibodies.

The workflow is illustrated in online supplemental figure 1. Sample testing results which were considered final and used in subsequent statistical analyses are capitalised and highlighted in bold.

### Demographic data and questionnaire design

We designed a questionnaire to capture sociodemographic information, potential sources and risks of exposure to SARS-CoV-2, as well as countermeasures against infection.

1. The following sociodemographic and biological variables were recorded:

Province, age, gender, job function, occupational risks, time spent in service during the pandemic (from 1 January 2020 to the date of the survey), comorbidities (heart disease, chronic respiratory pathology, obesity, chronic kidney disease, diabetes, hypertension, immunosuppressive treatment (corticoids, chemotherapy, HIV, others), pregnancy, other immunosuppression to be specified), COVID-19-like symptoms and reported past-PCR positive test (from 19 March 2020 to the date of the survey).

2. SARS-CoV-2 occupational risks were defined based on type of profession and working site. If an HCW could not exclusively be classified into one category, she/he was assigned to the higher risk category. The risk categories were defined as follows:

2.1. High risk: Personnel working in separate wards for the treatment of patients with COVID-19 including COVID-19 general wards and COVID-19 intensive care units (ICUs)—both strictly separated from non-COVID-19 wards—, and personnel working in front line wards such as the medical, surgical, paediatric and obstetric emergency room and the ICUs. Job functions included physicians and medical residents, nurses, other allied health professionals (eg, lab and radiology technicians, pharmacists, community agent, psychologists and social workers), and cleaning staff/catering staff/security officers.

2.2. Moderate risk: Personnel working in wards which may also have a higher risk for SARS-CoV-2 transmission if the patient has COVID-19, including non-COVID-19 specific medical, surgical, paediatrics and gynaecology and obstetrics hospitalisation wards, the operating room department, other external consultation (including family planning and advisory centre, prenatal consultation, psychosocial consultation, HIV testing service, vaccination clinic and field officers), radiology department and the laboratory. Job functions included physicians and medical residents, nurses, midwives other allied health professionals cleaning/catering staff and security officers. In addition, laboratory and radiology personnel were included in this category.

2.3. Low risk: Personnel having direct contact to patients outside of high and moderate risk categories. Job functions included physicians and medical residents, nurses, other allied health professionals and cleaning/catering staff and security officers, administrative staff, facility management with patient contact, technical staff and surface workers with patient contact pharmacy personnel with patients contact.

2.4. Very low risk: Personnel having no direct contact to patients. Job functions included other administrative staff, facility management without patient contact, pharmacy personnel without patients contact and technical staff and surface workers without patient contact.

3. Other occupational exposure and infection prevention and control measure variables were also recorded including the following: Collection of nasopharyngeal

swabs, direct physical contact with patients with COVID-19, presence during aerosol-generating procedure, exposures to biological fluids or patients' belongings, sufficient and regular availability of PPE or alcohol-based hand sanitizer, use of hand hygiene after patient consultation as well as after cleaning or aseptic procedures.

### Patient and public involvement

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.

### Statistical analysis

Serological outcome (positive, negative) and variables collected in the questionnaire were descriptively analysed including absolute numbers and relative proportions. Differences among HCWs testing seropositive or seronegative were assessed using Pearson's test of independence or Fisher's exact test. P values  $\leq 0.05$  were considered statistically significant. A logistic regression model was run to further assess factors associated with SARS-CoV-2 serological outcome (positive, negative), including variables with a p value of  $\leq 0.2$  in the bivariate analysis, as well as biological variables likely to create confounding (age, sex) and variables linked to the occupational risk group (initial model). The then refined most parsimonious model was fitted using the stepwise (bottom-up) method (Final Model). The goodness of fit of the model—the deviations (2 Log(Likelihood))—was calculated. Potential differences in the availability and use of PPE and infection control measures between rural and urban hospitals were also examined in bivariate analyses. All analyses were performed in the XLSTAT software.

### RESULTS

Among 1029 HCWs included in this study, 61.3% originated from urban hospitals and 38.7% from rural hospitals. A total of 58.9% of all HCWs were male, with a median age of 37 years (range: 18–85), and 41.1% were female, with a median age of 35 years (range: 18–70, [table 1](#)). The largest professional group was nurses (33.7%), and most participants were assigned to the moderate occupational risk group (44.8%) and had worked more than 6 months in the hospital during the pandemic. 7.5% of all participants had comorbidities. A majority (68.5%) had reported COVID-19-like symptoms previously, while 2% had had a PCR-confirmed SARS-CoV-2 infection before (including only four HCWs from rural sites, [table 2](#)).

Overall seroprevalence among HCWs in South Kivu hospitals was 33.1%. Of all 248 samples with a conclusive result from micro-NT, 197 (76.4%) contained neutralising antibodies.

The bivariate analysis indicated that seroprevalence was higher in urban areas (41.5%) as compared with rural areas (19.8%,  $p < 0.0001$ , [table 2](#)). It was higher in HCWs who had developed COVID-19-like symptoms previously (42.6%) compared with those who reported no symptoms (28.8%,  $p < 0.0001$ ), and also in those with a previous PCR-confirmed SARS-CoV-2 infection (57.1%) compared with those without a positive test (32.6%,  $p = 0.0182$ ). Seropositivity of HCWs was also higher among those who reported performing nasopharyngeal swabbing of patients with suspected COVID-19 (53.5%,  $p = 0.0038$ ), and having direct contact with patients with COVID-19 (37.8%,  $p = 0.0244$ , [table 2](#)).

The multivariable analysis including hospital site (urban/rural), professional risk group, professional activities with potential exposure to SARS-CoV-2, COVID-19-like symptoms and SARS-CoV-2 infection revealed that

**Table 1** SARS-CoV-2 seropositivity according to hospital sites and among female and male HCWs in South Kivu, DRC

	Overall	Female	Male
Total	1029	423/1029 (41.1%)	606/1029 (58.9%)
Rural zone	79/398 (19.8%)	26/151 (17.2%)	53/247 (21.5%)
Kakwende Health Centre	1/35 (2.9%)	0/17 (0.0%)	1/18 (5.6%)
Kavumu Health Centre	30/95 (31.6%)	12/34 (35.3%)	18/61 (29.5%)
Katana Hospital	18/72 (25.0%)	5/25 (20.0%)	13/47 (27.7%)
Kaziba Health Centre	12/89 (13.5%)	0/21 (0.0%)	12/68 (17.6%)
Walungu Hospital	18/107 (16.8%)	9/54 (16.7%)	9/53 (17.0%)
Urban zone	262/631 (41.5%)	120/272 (44.1%)	142/359 (39.6%)
BIOPHARM Health Centre	7/19 (36.8%)	5/10 (50.0%)	2/9 (22.2%)
Kasenga Hospital	21/58 (36.2%)	8/15 (53.3%)	13/43 (30.2%)
Nyantende Hospital	33/76 (43.4%)	14/35 (40.0%)	19/41 (46.3%)
Panzi Hospital	173/423 (40.9%)	81/188 (43.1%)	92/235 (39.1%)
Ciriri Hospital	19/39 (48.7%)	7/18 (38.9%)	12/21 (57.1%)
Kadutu Hospital	9/16 (56.3%)	5/6 (83.3%)	4/10 (40.0%)

DRC, Democratic Republic of the Congo; HCW, healthcare worker.

**Table 2** Demographic characteristics and SARS-CoV-2 exposures of HCWs in urban and rural hospitals in South Kivu, DRC

	Seronegative	Seropositive	P value*
Total	688/1029 (66.9%)	341/1029 (33.1%)	
Zone			
Rural	319/398 (80.2%)	79/398 (19.8%)	<b>&lt;0.0001</b>
Urban	369/631 (58.5%)	262/631 (41.5%)	
Age (years)			
18–25	91/124 (73.4%)	33/124 (26.6%)	0.4683
26–35	226/346 (65.3%)	120/346 (34.7%)	
36–45	158/240 (65.8%)	82/240 (34.2%)	
46–55	112/174 (64.4%)	62/174 (35.6%)	
56–65	78/109 (71.6%)	31/109 (28.4%)	
>65	23/36 (63.9%)	13/36 (36.1%)	
Gender			
Male	411/606 (67.8%)	195/606 (32.2%)	0.4332
Female	277/423 (65.5%)	146/423 (34.5%)	
Function			
Administrative	46/63 (73%)	17/63 (27%)	0.3303
Medical resident	41/68 (60.3%)	27/68 (39.7%)	
Nurse	235/347 (67.7%)	112/347 (32.3%)	
Technical and manual staff	183/268 (68.3%)	85/268 (31.7%)	
Physician	69/116 (59.5%)	47/116 (40.5%)	
Other allied health professional	114/167 (68.3%)	53/167 (31.7%)	
Professional risk group			
High	187/294 (63.6%)	107/294 (36.4%)	0.0659
Moderate	305/461 (66.2%)	156/461 (33.8%)	
Low	99/129 (76.7%)	30/129 (23.3%)	
Very low	97/145 (66.9%)	48/145 (33.1%)	
Time spent in service (months)			
≤2	54/74 (73.0%)	20/74 (27.0%)	0.5088
3–5	68/103 (66.0%)	35/103 (34.0%)	
≥6	566/852 (66.4%)	286/852 (33.6%)	
Comorbidities			
No	639/949 (67.3%)	310/949 (32.7%)	0.2669
Yes	49/80 (61.3%)	31/80 (38.8%)	
COVID-19-like symptoms			
No	502/705 (71.2%)	203/705 (28.8%)	<b>&lt; 0.0001</b>
Yes	186/324 (57.4%)	138/324 (42.6%)	
Reported past COVID-19 positive PCR			
No	679/1008 (67.4%)	329/1008 (32.6%)	<b>0.0182</b>
Yes	9/21 (42.9%)	12/21 (57.1%)	
Nasopharyngeal swabbing of patients			
No	668/986 (67.7%)	318/986 (32.3%)	<b>0.0038</b>
Yes	20/43 (46.5%)	23/43 (53.5%)	
Contact with patients with COVID-19			
No	476/688 (69.2%)	212/688 (30.8%)	<b>0.0244</b>
Yes	212/341 (62.2%)	129/341 (37.8%)	

Continued



Table 2 Continued

	Seronegative	Seropositive	P value*
Presence during aerosol generating procedure			
No	669/999 (67.0%)	330/999 (33.0%)	0.677
Yes	19/30 (63.3%)	11/30 (36.7%)	
Biological fluid exposure			
No	664/989 (67.1%)	325/989 (32.9%)	0.3471
Yes	24/40 (60.0%)	16/40 (40.0%)	
Had contact with patients' belongings			
No	657/981 (67.0%)	324/981 (33.0%)	0.7313
Yes	31/48 (64.6%)	17/48 (35.4%)	

\*P values <0.05 are highlighted in bold.

DRC, Democratic Republic of the Congo; HCW, healthcare worker.

working at urban hospitals and having had COVID-19-like symptoms were significant positive predictors of SARS-CoV-2 seropositivity of HCWs (table 3).

A detailed analysis of reported symptoms typical for COVID-19 in the past 8 months prior to the study revealed that loss of taste or smell (68.9%,  $p=0.001$ ), asthenia (57.6%,  $p=0.0058$ ), myalgia (51.9%,  $p=0.0195$ ) and cough (49.6%,  $p=0.0493$ ) were significantly associated with seropositivity (table 4).

PPE materials during the pandemic were reported as reliably available in only 50.5% of all considered hospitals, including 88.1% in urban hospitals compared with 11.9% in rural hospitals ( $p<0.0001$ , table 5). Urban hospitals also had more access to alcohol-based hand sanitizers compared with rural hospitals (71.1% and 28.9%, respectively,  $p<0.0001$ ). The vast majority of HCWs reported using hand hygiene at 'all times' or 'often' after patient contact (94.4%) and after cleaning contaminated materials (93.1%). Hand hygiene was significantly more often applied at urban (63.0% after consultation, 63.5% after cleaning) than at rural sites (37.0% after consultation, 36.5% after cleaning,  $p<0.0001$ , table 5).

## DISCUSSION

In the present study, we assessed the seroprevalence of SARS-CoV-2 and associated potential risk factors in 11 urban and rural hospitals in South Kivu, DRC, where differences in demography and infection prevention and control measures may influence SARS-CoV-2 exposure. We found that over one-third of 1029 HCWs were SARS-CoV-2 seropositive, indicating an overall high exposure to the virus during the first pandemic wave in 2020. 76.4% of 269 positive HCWs' sera contained neutralising antibodies, which is high compared with other studies,<sup>11</sup> which may indicate high levels of immune protection. Along with COVID-19 vaccination efforts, the high number of HCWs with (neutralising) antibodies in the first wave may thus also suggest the potential for greater protection against COVID-19 in subsequent pandemic

waves in DRC.<sup>11</sup> It should be noted that there are differences in the setups of assays used for the detection of neutralising antibodies among studies and therefore the results cannot easily be compared. The highly sensitive micro-neutralisation assay used in our study detects titres as low as 1:15, which likely results in an overall larger number of positive samples.<sup>13</sup>

Previous research conducted in the same region of Bukavu, based on a smaller sample of HCWs at two urban hospitals, revealed somewhat higher overall seroprevalence estimates (41.2%,<sup>8</sup> 40.5%<sup>14</sup>). The sampling period during the first pandemic wave in that study was, slightly earlier (May–August 2020) than in our study (August–October 2020). Anti-spike IgG antibody levels were shown to decrease significantly at 5–6 months compared with 0–3 months after infection in an Austrian population (by 44%<sup>15</sup>), and had a half-life of, for instance, 36 days in patients in the USA during the first pandemic wave.<sup>16</sup> This antibody decay potentially contributes to the observed lower seropositivity in the same region in our study. Comparisons of seroprevalences even during the limited time of pandemic wave one should thus be made with caution and consider the waning of antibodies over time.

Still, overall seroprevalence among HCWs employed during the first pandemic wave in 2020 varied widely on the African continent, from 1.2% in Cairo, Egypt (sampling in June 2020<sup>17</sup>), to 45.1% in Ibadan, Nigeria (exact study period in 2020 unknown<sup>18</sup>; reviewed by Müller *et al*,<sup>19</sup> with sampling periods of the included studies between April and December 2020). In Europe, rates of seropositive HCWs included similar to much lower estimates such as in the UK (31%, sampling period May–June 2020<sup>20</sup>), Italy (17.11%, sampling period May–June 2020<sup>21</sup>), Belgium (6% in April 2020<sup>22</sup>) and Germany (1.8% in July 2020<sup>23</sup>). The findings from the present study fall within the upper part of this range.

Rates of infection with SARS-CoV-2 early in the pandemic and subsequent seroprevalences were shown to

**Table 3** Logistic regression analysis of variables potentially affecting SARS-CoV-2 serological outcomes (positive, negative) among HCWs working in urban and rural hospitals in South Kivu, DRC

	Initial model		Final model	
	P value*	OR (95% CI)	P value*	OR (95% CI)
Zone				
Rural		Reference		
Urban	<b>&lt;0.0001</b>	2.6 (1.9 to 3.6)	<b>&lt;0.0001</b>	2.6 (1.9 to 3.5)
Professional risk group				
High		Reference		
Moderate	0.6371	0.9(0.7 to 1.3)		
Low	0.2706	0.8(0.5 to 1.2)		
Very low	<b>0.0230†</b>	0.6 (0.3 to 0.9)		
Gender				
Female		Reference		
Male	0.3846	0.9 (0.7 to 1.2)		
Age				
	0.1961	1 (1 to 1)		
Nasopharyngeal swabbing of patients				
No		Reference		
Yes	0.0808	1.8 (0.9 to 3.4)		
Contact with patients with COVID-19				
No		Reference		
Yes	0.2132	0.8 (0.6 to 1.1)		
Comorbidities				
No		Reference		
Yes	0.9282	1 (0.6 to 1.7)		
COVID-19-like symptoms				
No		Reference		
Yes	<b>0.0196†</b>	1.4 (1.1 to 1.9)	<b>0.0073</b>	1.5 (1.1 to 2)
Reported past COVID-19 positive PCR				
No		Reference		
Yes	0.13	2 (0.8 to 5.2)		

Variables with a p value of  $\leq 0.2$  in the bivariate analysis, possible confounders (age and sex) and variables linked to the occupational risk group were selected for the logistic regression analysis (initial model). The final model is obtained using stepwise (bottom-up) variable selection.

\*P values  $< 0.05$  are highlighted in bold.

†-2 Log(Likelihood).

DRC, Democratic Republic of the Congo; HCW, healthcare worker.

be affected, for instance, by the extent of and compliance with local lockdown measures.<sup>24</sup> In addition, most of the published HCW investigations represent urban hospital settings, and the causative link of seropositivity to urban versus rural settings has been much less often analysed. Our study revealed a twofold higher seroprevalence of SARS-CoV-2 in urban as compared with rural hospital sites. In another study conducted on the African continent in Zambia, no difference in seroprevalence among HCWs was detected in hospitals compared with smaller rural health centres, but no information on the size of the city or town was provided.<sup>25</sup> Studies from across the globe

show, however, regional differences (reviewed by Galanis *et al*<sup>9</sup>).

Although working in urban hospitals was significantly associated with SARS-CoV-2 seropositivity in South Kivu, a seroprevalence of 19.8% among also rural HCWs is striking, given that no cases from the same rural areas had yet been officially reported in DRC. In fact, virtually no HCWs from rural sites included in our study reported having been tested positive by PCR before at their respective hospitals. Also, at the urban sites very few HCWs had had a PCR-confirmed SARS-CoV-2 infection before (ie, 95% of seropositive HCWs were not tested positive

**Table 4** COVID-19-like symptoms according to SARS-CoV-2 seropositivity among HCWs employed at urban and rural hospitals in South Kivu, DRC

	Seronegative	Seropositive	P value*
	186/324 (57.4%)	138/324 (42.6%)	
Fever/chill	68/122 (55.7%)	54/122 (44.3%)	0.6367
Cough	61/121 (50.4%)	60/121 (49.6%)	<b>0.0493</b>
Loss of taste or smell	14/45 (31.1%)	31/45 (68.9%)	<b>0.0001</b>
Asthenia	28/66 (42.4%)	38/66 (57.6%)	<b>0.0058</b>
Body aches	50/104 (48.1%)	54/104 (51.9%)	<b>0.0195</b>
Rhinorrhea	82/144 (56.9%)	62/144 (43.1%)	0.8802
Sore throat	7/16 (43.8%)	9/16 (56.3%)	0.2572
Diarrhoea	20/38 (52.6%)	18/38 (47.4%)	0.5263
Shortness of breath	8/13 (61.5%)	5/13 (38.5%)	0.7585
Other symptoms	94/167 (56.3%)	73/167 (43.7%)	0.6741

\*P values <0.05 are highlighted in bold.  
DRC, Democratic Republic of the Congo; HCW, healthcare worker.

by PCR before, despite the presence of typical symptoms). This highlights the dramatic undertesting and under-reporting of SARS-CoV-2 cases in this region of DRC. Especially rural areas seem often to be neglected in containing the pandemic, as seen also in other Africa countries,<sup>3</sup> highlighting the importance of serological investigations. The finding that having had symptoms of COVID-19 before was associated with SARS-CoV-2 seropositivity among HCWs also underscores that testing of symptomatic HCWs is an important strategy to identify cases of COVID-19 and reduce further transmission. Like others, we showed that a significant proportion of seropositive HCWs remained asymptomatic,<sup>4 26</sup> demonstrating that routine testing strategies of exposed hospital

staff could have been an important strategy to mitigate the risk of COVID-19 transmission at healthcare facilities.

The inaccessibility of some rural areas due to poor transport infrastructure and insecurity in this particular region of DRC might explain the lower level of hygiene interventions and availability of PPE found in this study, and HCWs are at a potentially high risk of getting infected by patients with COVID-19. Also, the overall population incidence of SARS-CoV-2 at the densely populated urban sites is most likely higher than at rural sites given cross-border influx and high population movement. These are factors we could not control for in our analysis. Thus, higher reported infection prevention and control measures applied in urban hospitals—though shown to

**Table 5** Infection prevention and control materials and measures reported in urban and rural hospitals in South Kivu, DRC

	Rural	Urban	P value*
PPE always available when treating patients with COVID-19			
Yes	62/520 (11.9%)	458/520 (88.1%)	<b>&lt;0.0001</b>
No	336/509 (66.0%)	173/509 (34.0%)	
Alcohol based hand sanitizer available			
Yes	215/744 (28.9%)	529/744 (71.1%)	
Sometimes	169/264 (64.0%)	95/264 (36.0%)	<b>&lt;0.0001</b>
No	14/21 (66.7%)	7/21 (33.3%)	
Hand hygiene after consultation			
Often/always	359/971 (37.0%)	612/971 (63.0%)	<b>&lt;0.0001</b>
Rarely/never	39/58 (67.2%)	19/58 (32.8%)	
Hand hygiene after cleaning or aseptic procedures			
Often/always	350/958 (36.5%)	608/958 (63.5%)	<b>&lt;0.0001</b>
Rarely/never	48/71 (67.6%)	23/71 (32.4%)	

\*P values <0.05 are highlighted in bold.  
DRC, Democratic Republic of the Congo; PPE, personnel protective equipment.



be highly effective in preventing transmission (reviewed by Schoberer *et al*<sup>27</sup>)—do not translate into lower HCW seroprevalence at urban as compared with rural hospitals, and exposure of HCWs remains high in urban hospitals as reported by others (eg, in India<sup>28</sup> and the USA<sup>29</sup>).

## CONCLUSIONS

We show that inhabitants of urban as well as rural communities in South Kivu, DRC, were highly exposed to SARS-CoV-2 during the first pandemic wave the country was facing. Given the absence of publicly reported cases during this period at the rural sites, serological studies are highly relevant in revealing infection dynamics especially in regions with low diagnostic capacities. This, and discrepancies in the application of protective measures between urban and rural sites, should be considered in future pandemic response programmes.

### Author affiliations

- <sup>1</sup>Université Evangélique en Afrique, Bukavu, Congo (the Democratic Republic of the)  
<sup>2</sup>Panzi General Referral Hospital, Bukavu, Congo (the Democratic Republic of the)  
<sup>3</sup>Robert Koch Institute, Berlin, Germany  
<sup>4</sup>Département des Œuvres et Recherches Médicales, ECC-NK, Goma, Congo (the Democratic Republic of the)  
<sup>5</sup>Helmholtz Institute for One Health, Greifswald, Germany  
<sup>6</sup>Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), Kinshasa, Congo (the Democratic Republic of the)  
<sup>7</sup>ZIG4, Robert Koch Institute, Berlin, Germany

**Twitter** Jonathan Tunangoya Yoyu @YOYUJonathan1

**Acknowledgements** We thank all hospital managers and healthcare workers for the support and collaboration during data collection. The authors would like to acknowledge the German Ministry of Economic Cooperation (BMZ) for funding this study through the project 'Corona antibody testing amongst health staff in South Kivu' commissioned to the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), project number 19.2372.1-005.00. We are grateful for financial support by the African Network for improved Diagnostics, Epidemiology and Management of Common Infectious Agents (ANDEMIA; funded by the German Federal Ministry of Education and Research (BMBF), grant number 01KA1606).

**Contributors** TBC and ABK conceived the study. TBC, J-PBC, JTY, NH, MG, AK, EM, MR, NSK and RBA conducted the experiments. TBC, J-PBC, SK, JTY, ST, ACV and GS analysed the data. AN, FHL, TE and DM supervised the study and provided guidance for its implementation. TBC, J-PBC, JTY and GS wrote the first manuscript draft and all authors reviewed it and gave valuable input. All authors have read and agreed to the published version of the manuscript. GS was responsible for the overall content as the guarantor.

**Funding** This research was funded by the German Ministry of Economic Cooperation (BMZ, grant number 19.2372.1-005.00) and supported by funds from the German Federal Ministry of Education and Research (BMBF, the ANDEMIA project, grant number 01KA1606).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** Ethics approval was obtained from the South Kivu Provincial directorate of National Health Ethics Committee, under the reference number CNES 001/DPSK/153PM/2020. Written informed consent was obtained from all participants after having explained the study objectives and procedures. Data were only accessible to study staff, and personnel identifiers were removed for subsequent analyses.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Raw data are available from the authors on request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### ORCID iDs

Jonathan Tunangoya Yoyu <http://orcid.org/0009-0000-0312-2458>  
 Grit Schubert <http://orcid.org/0000-0003-4210-7060>

## REFERENCES

- Juma CA, Mushabaa NK, Abdu Salam F, *et al*. COVID-19: the current situation in the Democratic Republic of Congo. *Am J Trop Med Hyg* 2020;103:2168–70.
- Government of the Democratic Republic of the Congo. Epidémie de la Maladie À Coronavirus 2019 (COVID-19) en République Démocratique Du Congo - rapport de situation; 2022.
- Mukwege D, Cadière G-B, Vandenberg O. COVID-19 response in sub-Saharan low-resource setting: healthcare soldiers need bullets. *Am J Trop Med Hyg* 2020;103:549–50.
- Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. *Ann Intern Med* 2020;173:362–7.
- Buitrago-Garcia D, Ipekci AM, Heron L, *et al*. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. *PLoS Med* 2022;19:e1003987.
- Meyerowitz EA, Richterman A, Bogoch II, *et al*. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. *Lancet Infect Dis* 2021;21:e163–9.
- Shields A, Faustini SE, Perez-Toledo M, *et al*. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. *Thorax* 2020;75:1089–94.
- Mukwege D, Byabene AK, Akonkwa EM, *et al*. High SARS-CoV-2 seroprevalence in healthcare workers in Bukavu, Eastern democratic Republic of Congo. *Am J Trop Med Hyg* 2021;104:1526–30.
- Galanis P, Vraika I, Fragkou D, *et al*. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. *J Hosp Infect* 2021;108:120–34.
- Kabila Kabange J. Loi Organique N° 08/016 Du 07 octobre 2008 portant composition, organisation et fonctionnement des entités territoriales décentralisées et Leurs rapports avec L'Etat et LES provinces; 2008.
- Aziz NA, Corman VM, Echterhoff AKC, *et al*. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: results from a population-based study in Bonn, Germany. *medRxiv* [Preprint] 2020.
- Theel ES, Harring J, Hilgart H, *et al*. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. *J Clin Microbiol* 2020;58:e01243–20.
- Hofmann N, Grossegessle M, Neumann M, *et al*. Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2. *Sci Rep* 2022;12:3549.
- Katchunga PB, Murhula A, Akilimali P, *et al*. Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the saint Luc clinic in Bukavu, a city in Eastern democratic Republic of the Congo, from May to August 2020. *Pan Afr Med J* 2021;38:93.
- Siller A, Seekircher L, Wachter GA, *et al*. Seroprevalence, waning and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: large-scale study of 35,193 blood donors conducted between June 2020 and September 2021. *Viruses* 2022;14:568.
- Ibarondo FJ, Fulcher JA, Goodman-Meza D, *et al*. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. *N Engl J Med* 2020;383:1085–7.



- 17 Abdelmoniem R, Fouad R, Shawky S, *et al.* SARS-Cov-2 infection among asymptomatic healthcare workers of the emergency department in a tertiary care facility. *J Clin Virol* 2021;134:104710.
- 18 Olayanju O, Bamidele O, Edem F, *et al.* SARS-Cov-2 seropositivity in asymptomatic frontline health workers in Ibadan, Nigeria. *Am J Trop Med Hyg* 2021;104:91–4.
- 19 Müller SA, Wood RR, Hanefeld J, *et al.* Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence. *Health Policy Plan* 2022;37:505–13.
- 20 Grant JJ, Wilmore SMS, McCann NS, *et al.* Seroprevalence of SARS-Cov-2 antibodies in healthcare workers at a London NHS trust. *Infect Control Hosp Epidemiol* 2021;42:212–4.
- 21 Airoldi C, Patrucco F, Milano F, *et al.* High seroprevalence of SARS-Cov-2 among healthcare workers in a North Italy hospital. *Int J Environ Res Public Health* 2021;18:3343.
- 22 Steensels D, Oris E, Coninx L, *et al.* Hospital-wide SARS-Cov-2 antibody screening in 3056 staff in a tertiary center in Belgium. *JAMA* 2020;324:195–7.
- 23 Brehm TT, Schwinge D, Lampalzer S, *et al.* Seroprevalence of SARS-Cov-2 antibodies among hospital workers in a German tertiary care center: a sequential follow-up study. *Int J Hyg Environ Health* 2021;232:113671.
- 24 Amirthalingam G, Whitaker H, Brooks T, *et al.* Seroprevalence of SARS-Cov-2 among blood donors and changes after introduction of public health and social measures, London, UK. *Emerg Infect Dis* 2021;27:1795–801.
- 25 Fwoloshi S, Hines JZ, Barradas DT, *et al.* Prevalence of severe acute respiratory syndrome Coronavirus 2 among healthcare workers—Zambia. *Clin Infect Dis* 2021;73:e1321–8.
- 26 Ma Q, Liu J, Liu Q, *et al.* Global percentage of asymptomatic SARS-Cov-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. *JAMA Netw Open* 2021;4:e2137257.
- 27 Schoberer D, Osmancevic S, Reiter L, *et al.* Rapid review and meta-analysis of the effectiveness of personal protective equipment for healthcare workers during the COVID-19 pandemic. *Public Health Pract (Oxf)* 2022;4:100280.
- 28 Bhadra A, Mukherjee A, Sarkar K. Impact of population density on COVID-19 infected and mortality rate in India. *Model Earth Syst Environ* 2021;7:623–9.
- 29 Wong DWS, Li Y. Spreading of COVID-19: density matters. *PLoS One* 2020;15:e0242398.